Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7PWY

Structure of human dimeric ACMSD in complex with the inhibitor TES-1025

Summary for 7PWY
Entry DOI10.2210/pdb7pwy/pdb
Descriptor2-amino-3-carboxymuconate-6-semialdehyde decarboxylase, ZINC ION, 2-[3-[(5-cyano-6-oxidanylidene-4-thiophen-2-yl-1H-pyrimidin-2-yl)sulfanylmethyl]phenyl]ethanoic acid, ... (5 entities in total)
Functional Keywordsacmsd, de-novo nad+ synthesis, tes-1025, decarboxylase, lyase
Biological sourceHomo sapiens (human)
Total number of polymer chains4
Total formula weight153600.00
Authors
Cianci, M.,Giacche, N.,Carotti, A.,Liscio, P.,Amici, A.,Cialabrini, L.,De Franco, F.,Pellicciari, R.,Raffaelli, N. (deposition date: 2021-10-07, release date: 2022-04-20, Last modification date: 2024-01-31)
Primary citationCianci, M.,Giacche, N.,Cialabrini, L.,Carotti, A.,Liscio, P.,Rosatelli, E.,De Franco, F.,Gasparrini, M.,Robertson, J.,Amici, A.,Raffaelli, N.,Pellicciari, R.
Structural Basis of Human Dimeric alpha-Amino-beta-Carboxymuconate-epsilon-Semialdehyde Decarboxylase Inhibition With TES-1025.
Front Mol Biosci, 9:834700-834700, 2022
Cited by
PubMed Abstract: Human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) stands at a branch point of the NAD synthesis pathway and plays an important role in maintaining NAD homeostasis. It has been recently identified as a novel therapeutic target for a wide range of diseases, including inflammatory, metabolic disorders, and aging. So far, in absence of potent and selective enzyme inhibitors, only a crystal structure of the complex of human dimeric ACMSD with pseudo-substrate dipicolinic acid has been resolved. In this study, we report the crystal structure of the complex of human dimeric ACMSD with TES-1025, the first nanomolar inhibitor of this target, which shows a binding conformation different from the previously published predicted binding mode obtained by docking experiments. The inhibitor has a value of 0.85 ± 0.22 nM and binds in the catalytic site, interacting with the Zn metal ion and with residues belonging to both chains of the dimer. The results provide new structural information about the mechanism of inhibition exerted by a novel class of compounds on the ACMSD enzyme, a novel therapeutic target for liver and kidney diseases.
PubMed: 35463964
DOI: 10.3389/fmolb.2022.834700
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon